News
NXTC
1.570
+3.97%
0.060
Weekly Report: what happened at NXTC last week (0408-0412)?
Weekly Report · 3d ago
Promising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Rating
TipRanks · 04/08 15:45
Weekly Report: what happened at NXTC last week (0401-0405)?
Weekly Report · 04/08 09:18
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate, at the 2024 American Association for Cancer Research Annual Meeting in San Diego. The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
Barchart · 04/08 06:00
NEXTCURE APPOINTS DR. RAKESH DIXIT TO SCIENTIFIC ADVISORY BOARD
Reuters · 04/04 11:05
Press Release: NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer. Dr. Dixit's expertise is focused on antibody-drug conjugates.
Dow Jones · 04/04 11:05
Weekly Report: what happened at NXTC last week (0325-0329)?
Weekly Report · 04/01 09:18
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PyX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. In September 2023, the company's stock was trading below cash and data was expected in early 2024.
Seeking Alpha · 03/28 04:10
Weekly Report: what happened at NXTC last week (0318-0322)?
Weekly Report · 03/25 09:18
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
NextCure (NASDAQ:NXTC) has a negative free cash flow of US$54m over the last year. NextCure's cash burn relative to its market capitalisation is higher than the company's market value. The company has a 2.0 year runway to burn through its cash reserves. We look at Nextcure's rate of cash burn to see how the company is expected to grow in the future.
Simply Wall St · 03/23 14:55
12 Health Care Stocks Moving In Friday's After-Market Session
Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The company's market cap stands at $8.0 billion. Masimo shares rose 12.48% and NextCure shares declined by 9.5% during the same session.
Benzinga · 03/22 21:33
NextCure Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/22 18:26
NextCure Price Target Raised to $8.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 03/22 18:26
HC Wainwright & Co. Maintains Buy on NextCure, Raises Price Target to $8
Benzinga · 03/22 18:16
Promising Clinical Trial Results for NextCure’s NC410 Bolster Buy Rating
TipRanks · 03/22 10:17
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023
NextCure reported earnings per share of -52 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. NextCure's earnings were above the analyst estimate for -54 cents per share. The stock is down 1.7% today.
Investorplace · 03/22 02:54
NextCure Price Target Maintained With a $4.00/Share by Needham
Dow Jones · 03/21 19:09
NextCure Is Maintained at Buy by Needham
Dow Jones · 03/21 19:09
Needham Maintains Buy on NextCure, Maintains $4 Price Target
Benzinga · 03/21 18:59
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)
TipRanks · 03/21 18:30
More
Webull provides a variety of real-time NXTC stock news. You can receive the latest news about Nextcure through multiple platforms. This information may help you make smarter investment decisions.
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.